The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Open accessAbstract
BACKGROUND: Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas. METHODS: We performed genomewide analyses of 293 lower-grade gliomas from adults, incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA expression, microRNA expression, and targeted protein expression. These data were integrated and tested for correlation with clinical outcomes. RESULTS: Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had genomic aberrations and clinical behavior strikingly similar to those found in primary glioblastoma. CONCLUSIONS: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our patient’s tumor harbored mutations in TERT, FUBP1, and CIC, which are common alterations in oligodendroglioma, but not clinically relevant [46,47].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [47]
Experimental — accuracy not yet measuredIn the citing paper
“IDH WT astrocytomas are, for the most part, highly aggressive, having a median survival of 18 mo”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“Second, predicted risks are consistent with the published expected overall survivals associated with molecular subtypes (37).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“and these have the lowest overall predicted risks consistent with overall survivals of 10+ y (37, 39).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“IDH mutant astrocytomas are another subtype with considerably better overall survival ranging from 3 to 8 y”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“In recent years, two landmark genomic studies carried out in human glioma and acute myeloid leukaemia (AML) found mutations in IDH1/2 and it is now appreciated that these enzymes (which drive elevated production of D-2-HG) are the most frequently mutated metabolic genes in human cancer112-114.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,675
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Glioma Groups Based on 1p/19q, IDH , and TERT Promoter Mutations in Tumors
Eckel‐Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,981
Research works printed but not linked: 1
- Parker BC, 2013, J Clin Invest, 123, 855
Cited by
Sorted by citations
Items 801–900 of 1,002
Active DNA demethylation—The epigenetic gatekeeper of development, immunity, and cancer
Prasad, R. M., Yen, T. J., & Bellacosa, A. (2020) · Advanced Genetics · doi:10.1002/ggn2.10033 · Cited by 39
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
Sun, X., & Turcan, Ş. (2021) · Cells · doi:10.3390/cells10051225 · Cited by 38
Li, T., Yang, Z., Li, H., Zhu, J., Wang, Y., Tang, Q., & Shi, Z. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00682-7 · Cited by 37
Williamson, L. M., Rive, C. M., Francesco, D. D., Titmuss, E., Chun, H.-J. E., Brown, S. D., Milne, K., Pleasance, E., Lee, A. F., Yip, S. S. F., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00238-4 · Cited by 38
Ma, C., Wang, L., Song, D., Gao, C., Jing, L., Yang, L., Liu, D., Man, W., Yang, K., Meng, Z., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02898-4 · Cited by 37
Cuccarini, V., Erbetta, A., Farinotti, M., Cuppini, L., Ghielmetti, F., Pollo, B., DiMeco, F., Grisoli, M., Filippini, G., Finocchiaro, G., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1960-5 · Cited by 37
Ostrom, Q. T., Gittleman, H. R., Kruchko, C., Louis, D. N., Brat, D. J., Gilbert, M. R., Petkov, V. I., & Barnholtz‐Sloan, J. S. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2217-7 · Cited by 37
Ballester, L. Y., Fuller, G. N., Powell, S. Z.-E., Sulman, E. P., Patel, K. P., Luthra, R., & Routbort, M. J. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw119 · Cited by 37
Current therapeutic approaches to diffuse grade II and III gliomas
Pïcca, A., Berzero, G., & Sanson, M. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617752039 · Cited by 39
Ostrom, Q. T., Kinnersley, B., Armstrong, G., Rice, T., Chen, Y., Wiencke, J. K., Mccoy, L. S., Hansen, H. M., Amos, C. I., Bernstein, J. L., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31759 · Cited by 37
The role of NCAPG in various of tumors
Cai, X., Gao, J., Shi, C., Guo, W. Z., Guo, D., & Zhang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113635 · Cited by 36
Mechanistic Insights of Thyroid Cancer Progression
Leandro-Garcia, L. J., & Landa, I. (2023) · Endocrinology · doi:10.1210/endocr/bqad118 · Cited by 37
Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets
Ellrott, K., Wong, C. K., Yau, C. S. F., Castro, M. A. A., Lee, J., Karlberg, B., Grewal, J., Lagani, V., Tercan, B., Friedl, V., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2024.12.002 · Cited by 39
Use of big data in drug development for precision medicine
Kim, R. S., Goossens, N., & Hoshida, Y. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1174062 · Cited by 36
Zhao, S., Cai, J., Li, J., Bao, G., Li, D., Li, Y., Zhai, X., Jiang, C., & Fan, L. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0314-4 · Cited by 36
Tunneling nanotubes: A bridge for heterogeneity in glioblastoma and a new therapeutic target?
Venkatesh, V. S., & Lou, E. (2019) · Cancer Reports · doi:10.1002/cnr2.1185 · Cited by 37
Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas
Filipski, K., Braun, Y., Zinke, J., Roller, B., Baumgarten, P., Wagner, M., Senft, C., Zeiner, P. S., Ronellenfitsch, M. W., Steinbach, J. P., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02025-9 · Cited by 36
Zhang, Y., Pusch, S., Innes, J., Šidlauskas, K., Ellis, M. J., Lau, J., El-Hassan, T., Aley, N., Launchbury, F., Richard-Loendt, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0054 · Cited by 36
Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer
Guo, J., Zhang, R., Yang, Z., Duan, Z., Yin, D.-T., & Zhou, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644857 · Cited by 36
CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review
Yuile, A., Satgunaseelan, L., Wei, J., Rodriguez, M., Back, M., Pavlakis, N., Hudson, A. L., Kastelan, M., Wheeler, H., & Lee, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45070335 · Cited by 37
Fan, X., Wang, Y., Zhang, C., Liu, L., Yang, S., Wang, Y., Liu, X., Qian, Z., Fang, S., Qiao, H., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091276 · Cited by 36
Akyerli, C. B., Yüksel, Ş., Can, Ö., Erson-Omay, Z., Oktay, Y., Coşgun, E., Ülgen, E., Erdemgil, Y., Sav, A., von Deimling, A., et al. (2017) · Journal of neurosurgery · doi:10.3171/2016.11.jns16973 · Cited by 36
Palsgrove, D. N., Brosnan‐Cashman, J. A., Giannini, C., Raghunathan, A., Jentoft, M. E., Bettegowda, C., Gökden, M., Lin, D., Yuan, M., Lin, M., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0103-x · Cited by 36
Multiple Molecular Data Sets and the Classification of Adult Diffuse Gliomas
Ellison, D. W. (2015) · New England Journal of Medicine · doi:10.1056/nejme1506813 · Cited by 36
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
Lin, L., Cai, J., Tan, Z., Meng, X., Li, R., Yang, L., & Jiang, C. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.506 · Cited by 36
Romano, A., Palizzi, S., Romano, A., Moltoni, G., Napoli, A. D., Maccioni, F., & Bozzao, A. (2023) · Cancers · doi:10.3390/cancers15030618 · Cited by 35
Co-evolution of glioma and immune microenvironment
Elguindy, M. M., Young, J. S., Ho, W. S., & Lu, R. O. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009175 · Cited by 39
Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters
Viswanath, P., Najac, C., Izquierdo-García, J. L., Pankov, A., Hong, C., Eriksson, P., Costello, J., Pieper, R. O., & Ronen, S. M. (2016) · Oncotarget · doi:10.18632/oncotarget.9006 · Cited by 35
Drug repurposing for glioblastoma based on molecular subtypes
Chen, Y., & Xu, R. (2016) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2016.09.019 · Cited by 35
Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas
Qian, Z., Li, Y., Fan, X., Zhang, C., Wang, Y., Jiang, T., & Liu, X. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1434466 · Cited by 35
Poulen, G., Gozé, C., Rigau, V., & Duffau, H. (2018) · Journal of neurosurgery · doi:10.3171/2017.10.jns171825 · Cited by 35
Chaddad, A., Desrosiers, C., Abdulkarim, B., & Niazi, T. M. (2019) · IEEE Access · doi:10.1109/access.2019.2920396 · Cited by 35
Pouget, C., Hergalant, S., Lardenois, É., Lacomme, S., Houlgatte, R., Carpentier, C., Dehais, C., Rech, F., Taillandier, L., Sanson, M., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12788 · Cited by 35
Identification ofIDHandTERTpmutation status using1H‐MRS in 112 hemispheric diffuse gliomas
Öztürk-Işık, E., Cengiz, S. D., Özcan, A., Yakıcıer, C., Danyeli, A. E., Pamir, M. N., Özduman, K., & Di̇nçer, A. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26964 · Cited by 36
Jiang, C., Kong, Z., Zhang, Y., Liu, S., Liu, Z., Chen, W., Liu, P., Liu, D., Wang, Y., Lyu, Y., et al. (2020) · Neuroradiology · doi:10.1007/s00234-020-02392-1 · Cited by 35
Lin, W., Qiu, X., Sun, P., Ye, Y., Huang, Q., Kong, L., & Lu, J. J. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.04.010 · Cited by 38
Lyu, C., Niu, Y., Lai, W., Wang, Y., Wang, Y., Dai, P., Ma, C., Chen, S., Li, Y., Jiang, G., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00399-x · Cited by 35
Lasocki, A., Buckland, M. E., Drummond, K. J., Wei, H., Xie, J., Christie, M., Neal, A. J., & Gaillard, F. (2022) · Neuroradiology · doi:10.1007/s00234-022-02975-0 · Cited by 35
Eekers, D. B. P., Roelofs, E., Cubillos-Mesías, M., Niël, C., Smeenk, R. J., Hoeben, A., Minken, A., Granzier, M. E. P. G., Janssens, G. O. R. J., Kaanders, J. H. A. M., et al. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1529424 · Cited by 35
de Mendonça, M. L., Coletti, R., Gonçalves, C. S., Martins, E. P., Costa, B. M., Vinga, S., & Lopes, M. B. (2025) · Scientific Data · doi:10.1038/s41597-025-05117-2 · Cited by 35
Computational methods for detecting cancer hotspots
Martínez-Ledesma, E., Flores, D., & Treviño, V. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.11.020 · Cited by 34
Ye, M., Liu, J., Liu, X., Yuan, Q., Li, H., Zhang, Y., Zhan, Y., & Feng, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.951239 · Cited by 34
Hinrichs, B. H., Newman, S., Appin, C., Dunn, W. D., Cooper, L., Pauly, R., Kowalski, J., Rossi, M. R., & Brat, D. J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0270-7 · Cited by 34
Magnetic resonance analysis of malignant transformation in recurrent glioma
Jalbert, L. E., Neill, E., Phillips, J. J., Lupo, J., Olson, M. P., Molinaro, A. M., Berger, M. S., Chang, S. M., & Nelson, S. J. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now008 · Cited by 35
Hatae, R., Hata, N., Suzuki, S. O., Yoshimoto, K., Kuga, D., Murata, H., Akagi, Y., Sangatsuda, Y., Iwaki, T., Mizoguchi, M., et al. (2016) · Neuropathology · doi:10.1111/neup.12347 · Cited by 34
Multidimensional Integrative Genomics Approaches to Dissecting Cardiovascular Disease
Arneson, D. V., Shu, L., Tsai, B. L., Barrere‐Cain, R., Sun, C., & Yang, X. (2017) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00008 · Cited by 35
Granberg, K. J., Annala, M., Lehtinen, B., Kesseli, J., Haapasalo, J. A., Ruusuvuori, P., Yli-Harja, O. P., Visakorpi, T., Haapasalo, H. K., Nykter, M., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox028 · Cited by 34
Izquierdo, C., Barritault, M., Poncet, D., Cartalat‐Carel, S., Joubert, B., Bruna, J., Jouanneau, E., Guyotat, J., Vasiljevic, A., Fenouil, T., et al. (2018) · Neurosurgery · doi:10.1093/neuros/nyy513 · Cited by 35
Melatonin and its anti-glioma functions: a comprehensive review
Maitra, S., Bhattacharya, D., Das, S., & Bhattacharya, S. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0041 · Cited by 35
Suh, C. H., Kim, H. S., Paik, W., Choi, C., Ryu, K. H., Kim, D., Woo, D., Park, J. E., Jung, S. C., Choi, C. G., et al. (2019) · Radiology · doi:10.1148/radiol.2019182200 · Cited by 34
Diverse regulatory manners of human telomerase reverse transcriptase
Jie, M., Chang, X., Zeng, S., Liu, C., Liao, G., Wu, Y., Liu, C., Hu, C.-J., Yang, S., & Li, X. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0372-0 · Cited by 35
Vidman, L., Källberg, D., & Rydén, P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219102 · Cited by 34
Sato, K., Tahata, K., & Akimoto, K. (2020) · Anticancer Research · doi:10.21873/anticanres.14250 · Cited by 34
Topography of transcriptionally active chromatin in glioblastoma
Xu, L., Chen, Y., Huang, Y., Sandanaraj, E., Yu, J. S., Lin, R. Y., Dakle, P., Ke, X., Chong, Y. K., Koh, L., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd4676 · Cited by 35
Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas
Yu, G., Pang, Y. K., Merchant, M., Kesserwan, C. A., Gangalapudi, V., Abdelmaksoud, A. A., Ranjan, A., Kim, O., Wei, J. S., Chou, H.-C., et al. (2021) · Cancers · doi:10.3390/cancers13236092 · Cited by 34
Yeo, K. K., Alexandrescu, S., Cotter, J. A., Vogelzang, J. R., Bhave, V. M., Li, M. M., Ji, J., Benhamida, J. K., Rosenblum, M. K., Bale, T., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac132 · Cited by 34
TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing
Demirdizen, E., Al‐Ali, R., Narayanan, A., Sun, X., Varga, J. P., Steffl, B., Brom, M., Krunic, D., Schmidt, C., Schmidt, G., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac233 · Cited by 35
Stalled oligodendrocyte differentiation in IDH-mutant gliomas
Wei, Y., Li, G., Feng, J. H., Wu, F., Zhao, Z., Bao, Z., Zhang, W., Su, X., Li, J., Qi, X., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01175-6 · Cited by 36
Jungk, C., Scherer, M., Möck, A., Capper, D., Radbruch, A., von Deimling, A., Bendszus, M., Herold‐Mende, C. C., & Unterberg, A. W. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2177-y · Cited by 34
Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells
Leelatian, N., Sinnaeve, J., Mistry, A. M., Barone, S. M., Brockman, A. A., Diggins, K. E., Greenplate, A. R., Weaver, K. D., Thompson, R. C., Chambless, L. B., et al. (2020) · eLife · doi:10.7554/elife.56879 · Cited by 34
Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS -Wild-Type Melanoma Cell Lines
Verduzco, D., Kuenzi, B. M., Kinose, F., Sondak, V. K., Eroglu, Z., Rix, U., & Smalley, K. S. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0196 · Cited by 33
Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
Yang, X., Xing, Z., She, D., Lin, Y., Zhang, H., Su, Y., & Cao, D. (2022) · BMC Medical Imaging · doi:10.1186/s12880-022-00832-3 · Cited by 33
Chen, Z., Liu, A., Zhang, X., Cao, X., Ding, Z., Sha, Q., Shen, H., Deng, H., & Zhou, W. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108058 · Cited by 39
Kang, K. M., Song, J., Choi, Y., Park, C., Park, J. E., Kim, H. S., Park, S., Park, C., & Choi, S. H. (2024) · Radiology · doi:10.1148/radiol.233120 · Cited by 33
Cai, Y., Xiao, H., Xue, S., Li, P., Zhan, Z., Lin, J., Song, Z., Liu, J., Xu, W., Zhou, Q., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03301-1 · Cited by 33
Acharya, S., Robinson, C. G., Michalski, J. M., Mullen, D. F., DeWees, T. A., Campian, J. L., Chundury, A., Bottani, B., Hallahan, D. E., Bradley, J. D., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.01.099 · Cited by 33
Gladitz, J., Klink, B., & Seifert, M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0544-y · Cited by 33
Pangeni, R. P., Zhang, Z., Alvarez, A. A., Wan, X., Sastry, N. G., Lu, S., Shi, T., Huang, T., Lei, C. X., James, C. D., et al. (2018) · Epigenetics · doi:10.1080/15592294.2018.1469892 · Cited by 33
Xu, X., Bryke, C. R., SUKHANOVA, M. J., Huxley, E., Dash, D. P., Dixon‐McIver, A., Fang, M., Griepp, P., Hodge, J. C., Iqbal, M. A., et al. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.07.005 · Cited by 34
Lewis, M. A., Ganeshan, B., Barnes, A., Bisdas, S., Jaunmuktane, Z., Brandner, S., Endozo, R., Groves, A. M., & Thust, S. C. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.02.014 · Cited by 33
Castet, F., Alanya, E., Vidal, N., Izquierdo, C., Mesía, C., Ducray, F., Gil‐Gil, M., & Bruna, J. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03183-2 · Cited by 33
Pan, X., Zeng, T., Yuan, F., Zhang, Y., Chen, L., Zhu, L., Wan, S., Huang, T., & Cai, Y. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00339 · Cited by 33
Tectal glioma harbors high rates of KRAS G12R and concomitant KRAS and BRAF alterations
Chiang, J., Li, X., Liu, A. P. Y., Qaddoumi, I. A., Acharya, S., & Ellison, D. W. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02112-x · Cited by 33
Xiao, K., Liu, Q., Peng, G., Su, J., Qin, C., & Wang, X. (2020) · PeerJ · doi:10.7717/peerj.8312 · Cited by 33
Lin, J., Lin, N., & Zhao, W. (2020) · Genomics · doi:10.1016/j.ygeno.2020.05.016 · Cited by 33
Sun, C., Fan, L., Wang, W., Wang, W., Liu, L., Duan, W., Pei, D., Zhan, Y., Zhao, H., Sun, T., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.756828 · Cited by 33
Oncogenic and Tumor-Suppressive Functions of the RNA Demethylase FTO
Zuidhof, H. R., & Calkhoven, C. F. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3710 · Cited by 33
Lowenstein, P. R., & Castro, M. G. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.07.006 · Cited by 33
Wijnenga, M. M. J., French, P. J., Dubbink, H. J., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Fleischeuer, R. E. M., Dirven, C. M. F., Vincent, A. J. P. E., & van den Bent, M. J. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2867-8 · Cited by 33
Gliomas display distinct sex-based differential methylation patterns based on molecular subtype
Johansen, M. L., Stetson, L. C., Vadmal, V., Waite, K. A., Berens, M. E., Connor, J. R., Lathia, J. D., Rubin, J. B., & Barnholtz‐Sloan, J. S. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa002 · Cited by 33
Big data in forensic science and medicine
Lefèvre, T. (2017) · Journal of Forensic and Legal Medicine · doi:10.1016/j.jflm.2017.08.001 · Cited by 33
Dinevska, M., Widodo, S. S., Furst, L. M., Cuzcano, L., Fang, Y., Mangiola, S., Neeson, P. J., Darcy, P. K., Ramsay, R. G., Hutchinson, R. A., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-022-00763-9 · Cited by 32
Niu, N., Ye, J., Hu, Z., Zhang, J., & Wang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087076 · Cited by 34
Wu, P. B., Filley, A. C., Miller, M. L., & Bruce, J. N. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-23705-8_2 · Cited by 32
Deng, L., Di, Y., Chen, C., Xia, J., Lei, B., Li, N., & Zhang, Q. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06486-z · Cited by 32
Sensitivity to BUB1B Inhibition Defines an Alternative Classification of Glioblastoma
Lee, E., Pain, M., Wang, H., Herman, J., Toledo, C. M., DeLuca, J. G., Yong, R. L. M., Paddison, P. J., & Zhu, J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0736 · Cited by 32
Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics
Bahrami, N., Hartman, S. J., Chang, Y., Delfanti, R. L., White, N. S., Karunamuni, R. A., Seibert, T. M., Dale, A. M., Hattangadi-Gluth, J. A., Piccioni, D. E., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2908-3 · Cited by 32
Kim, D., Wang, N. C., Ravikumar, V., Raghuram, D. R., Li, J., Patel, A., Wendt, R. E., Rao, G., & Rao, A. U. K. (2019) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2019.00052 · Cited by 32
(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
Richardson, L. G., Choi, B. D., & Curry, W. T. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.01.08 · Cited by 32
GFAP alternative splicing regulates glioma cell–ECM interaction in a DUSP4‐dependent manner
van Bodegraven, E. J., van Asperen, J. V., Sluijs, J. A., Deursen, C. V., van Strien, M. E., Stassen, O. M. J. A., Robe, P. A. J. T., & Hol, E. M. (2019) · The FASEB Journal · doi:10.1096/fj.201900916r · Cited by 32
Zhang, Y., Lucas, C. G., Young, J. S., Morshed, R. A., Mccoy, L. S., Bush, N. A. O., Taylor, J. W., Daras, M., Butowski, N. A., Villanueva-Meyer, J. E., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac089 · Cited by 32
Chen, J., Shen, S., Li, Y., Fan, J., Xiong, S., Xu, J., Zhu, C., Lin, L., Dong, X., Duan, W., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104007 · Cited by 32
Bale, T., Jordan, J. T., Rapalino, O., Ramamurthy, N., Jessop, N. A., DeWitt, J. C., Nardi, V., Martinez‐Lage, M., Frosch, M. P., Batchelor, T. T., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy201 · Cited by 32
Using germline variants to estimate glioma and subtype risks
Eckel‐Passow, J. E., Decker, P. A., Kosel, M., Kollmeyer, T. M., Molinaro, A. M., Rice, T., Caron, A. A., Drucker, K. L., Praska, C. E., Pekmezci, M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz009 · Cited by 33
Updating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classification
Komori, T. (2020) · Brain Tumor Pathology · doi:10.1007/s10014-020-00358-y · Cited by 32
Long-term follow up of patients with WHO grade 2 oligodendroglioma
Carstam, L., Latini, F., Solheim, O., Bartek, J., Pedersen, L. K., Zetterling, M., Beniaminov, S., Sjåvik, K., Ryttlefors, M., Jensdottir, M., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04368-6 · Cited by 31
Liu, L., Wang, G., Wang, L., Yu, C., Li, M., Song, S., Hao, L., Ma, L., & Zhang, Z. (2020) · Biology Direct · doi:10.1186/s13062-020-00264-5 · Cited by 32
TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas
Zheng, J., Wang, L., Zhao, S., Zhang, W., Chang, Y., Bosco, D. B., Huang, T., Dheer, A., Gao, S., Xu, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad214 · Cited by 32
Aldape, K., Nejad, R., Louis, D. N., & Zadeh, G. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now181 · Cited by 31
Characterization of cytokinome landscape for clinical responses in human cancers
Wong, H. S.-C., Chang, C., Liu, X., Huang, W., & Chang, W. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214789 · Cited by 31
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- Emory University (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2481-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4530011
- OpenAlex
- W1812256879
- Cited by
- 3,148
- References
- 54
- Citations by year
- 2026: 139 · 2025: 196 · 2024: 248 · 2023: 282 · 2022: 371 · 2021: 341 · 2020: 366 · 2019: 314 · 2018: 311 · 2017: 284 · 2016: 226 · 2015: 60
- FWCI
- 164.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, U54HG007990)
- National Cancer Institute (U24CA194362, U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, U24CA143858, U24CA126543, U24CA144025, U24CA126563, U01CA168394, U24CA143866, U24CA143883, U24CA143845, U24CA126544, R01CA163722, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA008748, P30CA016672, U24CA143731)
- National Institute of Neurological Disorders and Stroke (R01NS081125)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioma molecular subtypes, IDH mutation, 1p/19q codeletion, TP53 mutation, TERT promoter mutation, NOTCH1 mutation, CIC mutation, glioblastoma, prognostic factors, DNA methylation, DNA copy number, gene expression, microRNA expression
- MeSH terms
- Adolescent, Adult, Aged, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, DNA, Neoplasm, Female, Glioblastoma, Glioma, Humans, Male, Middle Aged, Mutation, Signal Transduction, Cluster Analysis, Proportional Hazards Models, Genes, p53, Sequence Analysis, DNA, Kaplan-Meier Estimate, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
